Second Primary Cancer After Chimeric Antigen Receptor–T-Cell Therapy

Overview of attention for article published in JAMA Oncology, February 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
Good Attention Score compared to outputs of the same age and source (67th percentile)

Mentioned by

news: 3 news outlets
twitter: 43 X users

facebook: 1 Facebook page
bluesky: 5 Bluesky users

Readers on

mendeley: 15 Mendeley

So far, Altmetric has seen 5 Bluesky posts from 5 Bluesky users, with an upper bound of 2,300 followers.

Great overview on risks and reasons for secondary malignancies post-CAR-T therapies. Contribution of the CAR itself is minimal, despite the FDA's black box warning. Great work by Sylvester's Jay Spiegel. jamanetwork.com/journals/jam...

RP @yleyfman.bsky.social: Review suggests that there is limited data to suggest that inadvertent transgene insertion is associated with second primary cancers in the post–CAR-T setting. jamanetwork.com/journals/jam...

Review suggests that there is limited data to suggest that inadvertent transgene insertion is associated with second primary cancers in the post–CAR-T setting. jamanetwork.com/journals/jam...

Secondary malignancies after CAR-T jamanetwork.com/journals/jam...

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity, including 1 additional Bluesky posts.